Entitlement Offer Documents
Released
Released
Announcement PDF
ASX ANNOUNCEMENT
8 NOVEMBER 2023
Entitlement Offer Documents
Sydney, Australia – 8 November 2023 – Radiopharm Theranostics (ASX:RAD), a developer of a worldclass platform of radiopharmaceutical products for both diagnostic and therapeutic uses, is pleased to
announce that the Entitlement Offer announced on 31 October 2023 opens today.
Annexed to this announcement are the documents being dispatched to eligible and ineligible holders
today, as well as a copy of the Entitlement Offer information booklet.
The Entitlement Offer is currently expected to close at 5.00 pm (Sydney time) on Friday, 24 November
2023. The Company reserves its rights to close the Entitlement Offer early or otherwise vary the
timetable in accordance with the terms of the Entitlement Offer information booklet and the ASX Listing
Rules.
Further information is available at nreo.radiopharmtheranostics.com.
Phillip Hains
Joint Company Secretary
Important information
This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in
any other jurisdiction in which such an offer would be illegal. The securities referred to in this document have not been and will
not be registered under the United States Securities Act of 1933 (the ‘US Securities Act’), or under the securities laws of any
state or other jurisdiction of the United States and may not be offered or sold, directly or indirectly, within the United States,
unless the securities have been registered under the US Securities Act or an exemption from the registration requirements of
the US Securities Act is available.
This document may not be distributed or released in the United States.
This announcement contains certain ‘forward-looking statements’ within the meaning of the securities laws of applicable
jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as ‘may,’
‘should,’ ‘expect,’ ‘anticipate,’ ‘estimate,’ ‘scheduled’ or ‘continue’ or the negative version of them or comparable terminology.
Any forecasts or other forward looking statements contained in this announcement are subject to known and unknown risks
and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may
or may not be correct. There are usually differences between forecast and actual results because events and actual
circumstances frequently do not occur as forecast and these differences may be material. Radiopharm does not give any
representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking
statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking
statements.
Radiopharm Theranostics Limited
Suite 1, Level 3, 62 Lygon Street, Carlton South VIC 3053 Australia
ABN: 57 647 877 889
RADIOPHARM THERANOSTICS LIMITED
ACN 647 877 889
Entitlement Offer
information booklet
1 for 2.35 pro rata non-renounceable entitlement offer at $0.07 per Share.
Last date for acceptance and payment: 5.00pm (AEDT) on Friday, 24 November 2023
If you are an Eligible Shareholder, this is an important document that requires your
immediate attention. It should be read in its entirety. If, after reading this document you
have any questions about the securities being offered for issue under it or any other matter,
you should contact your stockbroker, solicitor, accountant or other professional adviser.
NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES
Lead Manager
Legal adviser
Table of contents
IMPORTANT NOTICES -------------------------------------------------------------------------------------- 1
Letter from the Chairman ---------------------------------------------------------------------------------- 2
Summary of the Entitlement Offer ------------------------------------------------------------------------ 4
Key dates ----------------------------------------------------------------------------------------------------- 4
Enquiries ----------------------------------------------------------------------------------------------------- 4
1
Investor presentation ------------------------------------------------------------------------------ 5
2
Description and effect of the Offer --------------------------------------------------------------20
3
4
2.1
Overview
20
2.2
Issue of additional Shares under the Top Up Facility
20
2.3
Lead Manager
21
2.4
Shortfall facility
21
2.5
Impact on control
21
2.6
Directors’ interests
22
2.7
Eligibility of Shareholders
22
2.8
Ranking of New Shares
23
2.9
Allotment
23
2.10
Capital structure
23
2.11
Existing Options
23
2.12
Effect on Radiopharm’s financial position
24
2.13
Broker handling fee
24
2.14
Information Availability
24
How to apply ---------------------------------------------------------------------------------------25
3.1
Shareholder’s choices
25
3.2
Taking up all of your Entitlement and participating in the Top Up Facility
25
3.3
Taking up part of your Entitlement and allowing the balance to lapse
25
3.4
Allow your Entitlement to lapse
26
3.5
Consequences of not accepting your Entitlement
26
3.6
Payment
26
3.7
Entitlement and Acceptance Form is binding
26
3.8
Brokerage and Stamp Duty
26
3.9
Notice to Nominees and Custodians
27
Principal risk factors ------------------------------------------------------------------------------28
Entitlement Offer information booklet
5
6
4.1
Factors influencing success and risk
28
4.2
Specific investment risks
28
4.3
General investment risks
31
4.4
Cautionary statement
32
Financial information------------------------------------------------------------------------------33
5.1
Historical and pro forma consolidated balance sheet as at 30 June 2023
33
5.2
Basis of preparation of financial information
34
5.3
Pro-forma adjustments to consolidated balance sheet
34
5.4
Pro forma cash flow statement as at 30 June 2023
34
Definitions ------------------------------------------------------------------------------------------35
Corporate directory ----------------------------------------------------------------------------------------38
Entitlement Offer information booklet
ii
IMPORTANT NOTICES
consult your professional tax adviser in connection with the Entitlement
Offer.
This Information Booklet is dated 8 November 2023. Capitalised terms in
this section have the meaning given to them in this Information Booklet.
Privacy
The Entitlement Offer is being made without a prospectus under section
708AA Corporations Act (as notionally modified by ASIC Corporations
(Non-Traditional Rights Issues) Instrument 2016/84). This Information
Booklet does not contain all of the information which a prospective investor
may require to make an informed investment decision. The information in
this Information Booklet does not constitute financial product advice and
does not take into account your investment objectives, financial situation or
particular needs.
This Information Booklet is important and should be read in its entirety
before deciding to participate in the Entitlement Offer. This Information
Booklet is not a prospectus under the Corporations Act and has not been
lodged with ASIC.
Radiopharm may make additional announcements after the date of this
Information Booklet and throughout the period that the Entitlement Offer is
open that may be relevant to your consideration about whether you should
participate in the Entitlement Offer.
No party other than Radiopharm has authorised or caused the issue of this
Information Booklet, or takes any responsibility for, or makes, any
statements, representations or undertakings in this Information Booklet.
By returning an Entitlement and Acceptance Form or otherwise paying for
your New Shares Top Up Shares through BPAY in accordance with the
instructions on the Entitlement and Acceptance Form, you acknowledge
that you have read this Information Booklet and you have acted in
accordance with and agree to the terms of the Entitlement Offer detailed in
this Information Booklet.
No overseas offering
This Information Booklet and the accompanying Entitlement and
Acceptance Form do not constitute an offer or invitation in any place in
which, or to any person to whom, it would not be lawful to make that offer
or invitation. In particular, this Information Booklet does not constitute an
offer to Ineligible Shareholders and may not be distributed in the United
States and the New Shares may not be offered or sold, directly or
indirectly, to persons in the United States.
This Information Booklet is not to be distributed in, and no offer of New
Shares or Top Up Shares is to be made in countries other than Australia
and New Zealand. The distribution of this Information Booklet (including
an electronic copy) in other jurisdictions may be restricted by law and
therefore persons who come into possession of this Information Booklet
should seek advice on and observe these restrictions. Any failure to comply
with these restrictions may constitute a violation of applicable securities
laws.
No action has been taken to register or qualify the Entitlement Offer, the
Entitlements or the New Shares, or otherwise permit the public offering of
the New Shares, in any jurisdiction outside Australia and New Zealand.
Foreign exchange control restrictions or restrictions on remitting funds from
your country to Australia may apply. Your Application for New Shares is
subject to all requisite authorities and clearances being obtained for
Radiopharm to lawfully receive your Application Monies.
New Zealand
The New Shares are not being offered or sold to the public within New
Zealand other than to existing Radiopharm shareholders with registered
addresses in New Zealand to whom the offer of New Shares is being made
in reliance on the Financial Markets Conduct (Incidental Offers) Exemption
Notice 2016 (New Zealand).
This document has not been registered, filed with or approved by a New
Zealand regulatory authority under the Financial Markets Conduct Act 2013
(New Zealand). This document is not an investment statement or
prospectus under New Zealand law and is not required to, and may not,
contain all the information that an investment statement or prospectus
under New Zealand law is required to contain.
Definitions, currency and time
Defined terms used in this Information Booklet are contained in section 6.
All references to currency are to Australian dollars and all references to
time are to Australian Eastern Daylight Time (AEDT), unless otherwise
indicated.
Taxation
There will be tax implications associated with participating in the
Entitlement Offer and receiving New Shares. Radiopharm considers that it
is not appropriate to give advice regarding the tax consequences of
subscribing for New Shares under this Information Booklet or the
subsequent disposal of any New Shares. Radiopharm recommends that you
Entitlement Offer information booklet
Radiopharm collects information about each Applicant provided on an
Entitlement and Acceptance Form for the purposes of processing the
Application and, if the Application is successful, to administer the
Applicant's shareholding in Radiopharm.
By submitting an Entitlement and Acceptance Form, you will be providing
personal information to Radiopharm (directly or through the Share
Registry). Radiopharm collects, holds and will use that information to
assess your Application. Radiopharm collects your personal information to
process and administer your shareholding in Radiopharm and to provide
related services to you. Radiopharm may disclose your personal
information for purposes related to your shareholding in Radiopharm,
including to the Share Registry, Radiopharm's related bodies corporate,
agents, contractors and third-party service providers, including mailing
houses and professional advisers, and to ASX and regulatory bodies. You
can obtain access to personal information that Radiopharm holds about
you. To make a request for access to your personal information held by (or
on behalf of) Radiopharm, please contact Radiopharm through the Share
Registry.
Governing law
This Information Booklet, the Entitlement Offer and the contracts formed
on acceptance of the Applications are governed by the law applicable in
Victoria, Australia. Each Applicant submits to the exclusive jurisdiction of
the Victorian courts and courts competent to hear appeals from those
courts.
No representations
No person is authorised to give any information or to make any
representation in connection with the Entitlement Offer which is not
contained in this Information Booklet. Any information or representation in
connection with the Entitlement Offer not contained in the Information
Booklet may not be relied upon as having been authorised by Radiopharm
or any of its officers.
Past performance
Investors should note that Radiopharm’s past performance, including past
share price performance, cannot be relied upon as an indicator of (and
provides no guidance as to) Radiopharm’s future performance including
Radiopharm’s future financial position or share price performance.
Future performance
This Information Booklet contains certain forward-looking statements with
respect to the financial condition, results of operations, projects and
business of Radiopharm and certain plans and objectives of the
management of Radiopharm. These forward-looking statements involve
known and unknown risks, uncertainties and other factors which are
subject to change without notice, and may involve significant elements of
subjective judgement and assumptions as to future events which may or
may not be correct.
Forward-looking statements are provided as a general guide only and there
can be no assurance that actual outcomes will not differ materially from
these statements. Neither Radiopharm, nor any other person, gives any
representation, warranty, assurance or guarantee that the occurrence of
the events expressed or implied in any forward-looking statement will
actually occur. In particular, those forward-looking statements are subject
to significant uncertainties and contingencies, many of which are outside
the control of Radiopharm. A number of important factors could cause
actual results or performance to differ materially from the forward-looking
statements. Investors should consider the forward-looking statements
contained in this Information Booklet in light of those disclosures.
Risks
Refer to the ‘Risk factors’ section of the Investor Presentation included in
section 1 of this Information Booklet and in section 4 of this Information
Booklet for a summary of general and specific risk factors that may affect
Radiopharm.
Letter from the Chairman
8 November 2023
Dear fellow Shareholder,
On 31 October 2023, Radiopharm Theranostics Limited (Radiopharm or Company) announced its
intention to undertake an equity raising and it gives me great pleasure to offer you this opportunity to
increase your investment in the Company through participation in this 1 for 2.35 non-renounceable pro
rata rights issue of new Radiopharm Shares (New Shares) at a price of $0.07 per Share (Entitlement
Offer).
The Board intends to use the proceeds of the Entitlement Offer to progress its four clinical trials towards
the achievement of multiple inflection points, including RAD 301 Imaging Phase I read out, RAD 101
Imaging Phase IIb recruitment, RAD 204 Phase 1 Therapeutic recruitment and RAD 202 Phase 1
Therapeutic recruitment. Funds will also be applied to the ongoing working capital and the costs of the
Entitlement Offer.
Over the past 12 months, we have continued to make positive progress and we remain focused on
building momentum, meeting the many milestones ahead and generating shareholder value. Some key
events include:
Key event
Status
Date
Pivalate
Positive Phase 2a data in brain mets study
October 2022
December 2022
Trivehexin (Integrin)
FDA IND approval received for Phase 1 in
pancreatic cancer
Orphan Drug status granted for by FDA
May 2023
Nano-mAbs HER-2
Positive pre-IND (Type A) meeting with FDA
February 2023
MD Anderson Joint
Venture
Research and development agreement signed
with one of the world’s leading cancer centre
November 2022
Isotope supply chain
Secured with multiple global Supply
Agreements for Lu-177, Ac-225 and Tb-161
October 2023
Nano-mAbs non-small
Cell Lung Cancer RAD
204
Australian Ethics approval for Phase 1 clinical
trial
October 2023
The Entitlement Offer allows you to acquire New Shares in the Company at a price of $0.07 per New
Share (Offer Price). The Offer Price represents:
a 23.1% discount to the TERP1 of $0.091;
1
The theoretical ex-rights price of $0.091 is calculated using Radiopharm’s closing price on 30 October 2023
assuming proceeds from the Entitlement Offer of approximately $10 million. TERP is the theoretical price at which
shares should trade immediately after the ex-date for the Entitlement Offer assuming 100% take-up of the
Entitlement Offer. TERP is a theoretical calculation only and the actual price at which shares trade immediately after
the ex-date for the Entitlement Offer will depend on many factors and may not be equal to the TERP.
Entitlement Offer information booklet
2
a 30.0% discount to the last traded price of Radiopharm shares on 30 October 2023 of $0.10;
and
a 46.2% discount to the 15-day volume weighted average price (VWAP) of $0.13.
The number of New Shares you are entitled to subscribe for under the Entitlement Offer (Entitlement)
is set out in your personalised Entitlement and Acceptance Form that is attached to this Information
Booklet.
The Entitlement Offer is non-renounceable and therefore your Entitlements will not be tradeable on ASX
or otherwise transferable.
I would encourage Eligible Shareholders to participate in the Entitlement Offer given the attractive terms,
and all Directors eligible to participate in the Entitlement Offer, including myself, will do so.
The Entitlement Offer closes at 5.00pm (AEDT) on Friday, 24 November 2023.
Please read in full the details on how to submit your application, which are set out in this Information
Booklet. For further information about the Entitlement Offer, please call the share registry, Automic Pty
Ltd, on 1300 288 664 (within Australia) or +61 2 9698 5414 (outside Australia), or visit the Company’s
website at www.radiopharmtheranostics.com.
An investment in the Company should be considered as speculative and is subject to general and specific
risks which are set out in section 4. Specific risks include products in development not approved for
commercial sale, clinical trial risk, regulatory and reimbursement approvals, commercialisation of
products and potential market failure, dependence upon key personnel, arrangements with third-party
collaborators, risk of delay and continuity of operations, competition, requirement to raise additional
funds, growth and intellectual property.
You should also consult your stockbroker, solicitor, accountant or other professional adviser to evaluate
whether or not to participate in the Entitlement Offer.
On behalf of the Board, I encourage you to consider this investment opportunity and thank you for your
ongoing support.
Yours faithfully
Paul Hopper
Executive Chairman
Radiopharm Theranostics Limited
Entitlement Offer information booklet
3
Summary of the Entitlement Offer
Entitlement Offer
Ratio
1 New Share for every 2.35 existing Radiopharm Shares
Issue Price
$0.07 per New Share
Size
Approximately 144 million New Shares
Gross proceeds
Up to approximately $10 million
Key dates
Activity
Date
Announcement of Entitlement Offer
Tuesday, 31 October 2023
Record Date for determining Entitlements (7.00pm AEDT)
Friday, 3 November 2023
Information Booklet and Entitlement and Acceptance Form
despatched
Wednesday, 8 November 2023
Entitlement Offer opens
Wednesday, 8 November 2023
Entitlement Offer closes (5.00pm AEDT)
Friday, 24 November 2023
New Shares quoted on a deferred settlement basis
Monday, 27 November 2023
Announcement of results of the Entitlement Offer
Friday, 1 December 2023
Allotment of New Shares under the Entitlement Offer
Friday, 1 December 2023
Despatch of holding statements for New Shares issued under the
Entitlement Offer
Monday, 4 December 2023
Trading of New Shares under the Entitlement Offer commences
Tuesday, 5 December 2023
Notes: All times are in Australian Eastern Daylight Time (AEDT) unless otherwise stated.
This timetable is indicative only and subject to change. The Directors may vary these dates subject to the Listing Rules. An
extension of the Closing Date will delay the anticipated date for issue of the New Shares. The Directors also reserve the right not to
proceed with the whole or part of the Entitlement Offer any time before the allotment and issue of the New Shares. In that event,
the relevant Application Monies (without interest) will be returned in full to Applicants.
Enquiries
For further information, telephone please contact the share registry, Automic Registry Services on 1300
288 664 (inside Australia) or +61 2 9698 5414 (outside Australia) between 8.30am and 5.00pm (AEDT).
Alternatively, contact your stockbroker, solicitor, accountant or other professional adviser. If you have
lost your Entitlement and Acceptance Form and would like a replacement form, you should contact the
Share Registry.
Entitlement Offer information booklet
4
1
Investor presentation
Entitlement Offer information booklet
5
Entitlement Offer information booklet
6
Entitlement Offer information booklet
7
Entitlement Offer information booklet
8
Entitlement Offer information booklet
9
Entitlement Offer information booklet
10
Entitlement Offer information booklet
11
Entitlement Offer information booklet
12
Entitlement Offer information booklet
13
Entitlement Offer information booklet
14
Entitlement Offer information booklet
15
Entitlement Offer information booklet
16
Entitlement Offer information booklet
17
Entitlement Offer information booklet
18
Entitlement Offer information booklet
19
2
Description and effect of the Offer
2.1
Overview
The Entitlement Offer is a non-renounceable offer of New Shares at $0.07 per New Share to raise
about $10 million (before direct offer costs including fees paid to advisers and to providers of
specific services to cover share registry, printing and postage costs).
The Board intends to use the proceeds of the Entitlement Offer to progress its four clinical trials
towards the achievement of multiple inflection points, including RAD 301 Imaging Phase I read
out, RAD 101 Imaging Phase IIb recruitment, RAD 204 Phase 1 Therapeutic recruitment and RAD
202 Phase 1 Therapeutic recruitment.
Funds will also be applied for ongoing working capital and the costs of the Entitlement Offer.
Eligible Shareholders who are on Radiopharm’s share register on the Record Date are entitled to
acquire 1 New Share for every 2.35 Shares held on the Record Date (Entitlement).
Fractional Entitlements will be rounded down to the nearest whole number of New Shares.
The issue price of $0.07 per New Share represents a:
(a)
23.1% discount to the TERP of $0.091;
(b)
30.0% discount to the last traded price of Radiopharm shares on 30 October 2023 of
$0.10; and
(c)
46.2% discount to the 15-day VWAP of $0.13.
The Entitlement Offer is non-renounceable. Accordingly, Entitlements do not trade on ASX, nor
can they be transferred or otherwise disposed of.
An Entitlement and Acceptance Form setting out your Entitlement accompanies this Information
Booklet. Eligible Shareholders may subscribe for all or part of their Entitlement.
Eligible Shareholders who do not take up all of their Entitlements will have their percentage
shareholding in Radiopharm diluted.
Eligible Shareholders should be aware that an investment in Radiopharm involves risks. The key
risks identified by Radiopharm are summarised in the Investor Presentation set out in section 1
and in section 4 of this Information Booklet.
2.2
Issue of additional Shares under the Top Up Facility
Any New Shares not taken up by the Closing Date may be made available to those Eligible
Shareholders who took up their full Entitlement and applied for additional New Shares under the
Top Up Facility.
There is no guarantee that those Shareholders will receive the number of New Shares applied for
under the Top Up Facility, or any. The number of New Shares available under the Top Up Facility
will not exceed the shortfall from the Entitlement Offer. The Directors reserve the right to allot
and issue New Shares under the Top Up Facility at their discretion.
Entitlement Offer information booklet
20
2.3
Lead Manager
The Company has engaged Bell Potter Securities Limited ACN 006 390 772 (Bell Potter) to act
as Lead Manager to the Entitlement Offer (including any shortfall to the Entitlement Offer)
pursuant to the terms of the Lead Manager mandate.
Bell Potter will receive the following fees for its Lead Manager and offer management services:
(a)
7.5 million unlisted adviser options exercisable at $0.11 per option at any time up until
1 July 2028; and
(b)
6% of any Shares placed by Bell Potter as part of any shortfall to the Entitlement Offer.
Bell Potter will also be reimbursed up to $30,000 for legal fees if they underwrite the Entitlement
Offer. No other out-of-pocket expenses will be payable to Bell Potter.
The Lead Manager mandate otherwise contains terms and conditions considered standard for an
agreement of this type.
2.4
Shortfall facility
A shortfall may arise if applications received for New Shares under the Entitlement Offer
(including after the completion of the Top Up Facility (if any) and the Entitlements of Ineligible
Shareholders) are less than the number of New Shares offered.
The Directors reserve the right, subject to the requirements of the Listing Rules and the
Corporations Act, to place Shortfall Shares within three months after the Closing Date to either
existing or new Shareholders at their discretion. If issued, Shortfall Shares will be issued at a
price not less than the Issue Price of New Shares under the Entitlement Offer. Shareholders will
not receive any payment or value for the Entitlements not taken up under the Entitlement Offer
that are subsequently taken up as Shortfall Shares.
2.5
Impact on control
The following Shareholders have a substantial holding in Radiopharm:
Shareholder
Shares
Percentage interest
Mr Paul Hopper
94,221,428
27.8%
NanoMab Technology Limited
28,295,131
8.3%
Mr Hopper reserves the right to take up all or some of his entitlements under the Entitlement
Offer. By way of illustration, set out below is a table containing several theoretical outcomes
depending on Mr Hopper’s participation in the Entitlement Offer and the impact it would have on
his Voting Power, depending on the participation of other Eligible Shareholders.
25%
Shareholder
% take-up
Mr Paul Hopper
Entitlement Offer information booklet
Shares
Offer Subscribed at
50%
75%
100%
Percentage interest
0%
94,221,428
25.1%
22.9%
21.1%
19.5%
25%
104,244,984
27.8%
25.3%
23.3%
21.6%
50%
114,268,540
30.4%
27.8%
25.5%
23.6%
21
25%
Shareholder
% take-up
Mr Paul Hopper
Shares
Offer Subscribed at
50%
75%
100%
Percentage interest
75%
124,292,096
33.1%
30.2%
27.8%
25.7%
100%
134,315,652
35.8%
32.6%
30.0%
27.8%
Notwithstanding the above, any increase in Mr Hopper’s voting power in Radiopharm as a result
of his participation in the Entitlement Offer shall be structured to fall within the 3% creep
exemption available under the Corporations Act.
Accordingly, given the structure of the Entitlement Offer as a pro rata offer, the potential effect
that the issue of the New Shares will have on the control of Radiopharm is as follows:
2.6
(a)
if all eligible shareholders take up their Entitlement for New Shares under the Entitlement
Offer, the Entitlement Offer will have no effect on the control of Radiopharm;
(b)
to the extent that any Eligible Shareholder fails to take up their Entitlement for New
Shares under the Entitlement Offer, that Eligible Shareholder’s percentage holding in
Radiopharm will be diluted by those other Eligible Shareholders who take up some, all or
more than their Entitlement;
(c)
although the issue of New Shares which are not taken up by Eligible Shareholders under
the Entitlement Offer may increase the voting power of those Eligible Shareholders who
take up some, all or more than their Entitlement, Radiopharm does not expect that any
person will increase their percentage shareholding in Radiopharm in a way which will
have a material impact on the control of Radiopharm and does not expect any material
consequences to flow from that.
Directors’ interests
The Directors or their associates have a beneficial interest in the following Shares and Existing
Options at the date of this Information Booklet:
Director
Existing Shares
Existing Options
Hester Larkin
66,114
1,900,002
Ian Turner
800,000
3,621,934
Leila Alland
Nil*
1,900,002
Michael Baker
45,983
1,906,262
Paul Hopper
94,221,428
7,781,757
Riccardo Canevari
6,724,769
22,397,118
Note: Options subject to shareholder approval are not included in the above table.
*Directors not eligible to participate in the Entitlement Offer.
The eligible Directors intend to apply for New Shares under the Entitlement Offer.
2.7
Eligibility of Shareholders
The Entitlement Offer is being offered to all Eligible Shareholders.
Entitlement Offer information booklet
22
An Eligible Shareholder is a Shareholder on the Record Date who:
(a)
has a registered address on the Radiopharm share register in Australia and New Zealand
or is a Shareholder that Radiopharm has otherwise determined is eligible to participate;
(b)
is
Share your feedback
Discover